Compounded GLP-1 Online

What is retatrutide?

Retatrutide is an investigational triple receptor agonist being studied for weight loss, type 2 diabetes, and other weight-related conditions. In clinical trials, it is given as a once-weekly injection under the skin (subcutaneous injection).

Retatrutide works by targeting the receptors for three hormones: GIP, GLP-1, and glucagon, which are involved in appetite, blood sugar, and metabolism. Because it acts on all three receptors, it has been called a “triple agonist”, “triple G” weight-loss medicine, or GLP3.

Retatrutide is related to other incretin-based medicines such as semaglutide and tirzepatide. Semaglutide (Ozempic, Wegovy) acts on the GLP-1 receptor, and tirzepatide (Mounjaro, Zepbound) acts on the GIP and GLP-1 receptors.

Retatrutide acts on three receptors: GIP, GLP-1, and glucagon. Having glucagon receptor activity is what sets retatrutide apart from currently approved medicines, and researchers are studying how this added action affects weight loss and other health outcomes.

What do GIP, GLP-1, and GCG stand for?

• GIP = glucose-dependent insulinotropic polypeptide
• GLP-1 = glucagon-like peptide-1
• GCG = glucagon

These are natural hormones. Retatrutide works by activating the receptors these hormones normally act on.

How does retatrutide work?

Retatrutide works by activating the GIP, GLP-1, and glucagon receptors, which are involved in appetite, blood sugar, and metabolism.

The GIP and GLP-1 receptors may support weight loss and blood sugar control by:

• increasing insulin release when blood sugar rises
• improving how the body takes up glucose
• increasing feelings of fullness
• slowing digestion

The glucagon (GCG) receptor may add further benefit by:

• increasing the amount of energy the body burns
• increasing the breakdown of body fat
• reducing how much fat is stored